Valuation: Navana Pharmaceuticals PLC

Market Cap 7.74B 63.05M 56.02M 52.29M 47.66M 89.88M 6.06B 90.72M 633M 245M 3.1B 237M 232M 9.94B P/E 2024
23.2x
P/E 2025 11.1x
Enterprise Value 12.17B 99.12M 88.07M 82.2M 74.92M 141M 9.53B 143M 995M 385M 4.87B 372M 364M 15.63B EV / Sales 2024
2.09x
EV / Sales 2025 1.11x
Free-Float
68.17%
Yield 2024
1.6%
Yield 2025 2.78%
1 day-0.94%
1 week-0.78%
Current month-0.94%
1 month-6.07%
3 months-11.31%
6 months+10.05%
Current year+22.35%
1 week 62.6
Extreme 62.6
65.3
1 month 60
Extreme 60
68.1
Current year 50.7
Extreme 50.7
78
1 year 45.5
Extreme 45.5
78
3 years 36.2
Extreme 36.2
118.9
5 years 26.4
Extreme 26.4
132
10 years 26.4
Extreme 26.4
132
Manager TitleAgeSince
Chief Executive Officer 65 25/11/2020
Director of Finance/CFO - 01/07/2024
Chief Operating Officer 66 01/10/2020
Director TitleAgeSince
Director/Board Member 65 25/11/2020
Director/Board Member 56 25/11/2020
Director/Board Member 48 25/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%-0.78%+10.63%-28.57% 55.53M
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.78%-2.94%+24.53%+50.16% 369.72B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2024 2025
Net sales 6.9B 56.16M 49.9M 46.57M 42.45M 80.06M 5.4B 80.8M 564M 218M 2.76B 211M 206M 8.86B 8.84B 71.99M 63.97M 59.7M 54.42M 103M 6.92B 104M 722M 280M 3.54B 270M 264M 11.35B
Net income 405M 3.29M 2.93M 2.73M 2.49M 4.7M 317M 4.74M 33.06M 12.81M 162M 12.37M 12.1M 520M 488M 3.97M 3.53M 3.29M 3M 5.66M 382M 5.71M 39.86M 15.44M 195M 14.91M 14.59M 626M
Net Debt 5.03B 40.97M 36.4M 33.97M 30.97M 58.4M 3.94B 58.95M 411M 159M 2.01B 154M 150M 6.46B 4.43B 36.07M 32.04M 29.91M 27.26M 51.41M 3.47B 51.89M 362M 140M 1.77B 135M 132M 5.69B
Logo Navana Pharmaceuticals PLC
Navana Pharmaceuticals PLC., formerly Navana Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. It operates in two segments: Human Health and Veterinary. The Human Health segment is engaged in manufacturing marketing and selling of pharmaceutical products. It produces tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, eye drops, creams, ointments, and others. The Veterinary segment is engaged in manufacturing marketing distributing and selling of veterinary, poultry and fisheries products. The Company's products include Pmec, Stenide Cream, Agonil Cream, Vontac Tablet, Floxacin, Inpen, Osmina, Methebac, Kcit, Ezitor, Droniva, Ospemifene, Ferri Maltol, Lvofloxacin, Nafgal, Esona, Clonipres, Meltix, Diplin, and Arokast, among others.
Employees
4,798
Date Price Change Volume
01/10/26 BDT 63.50 -0.94% 220,458
30/09/26 BDT 64.10 +2.07% 439,882
29/09/26 BDT 62.80 -0.48% 203,400
28/09/26 BDT 63.10 +0.48% 161,353
27/09/26 BDT 62.80 -1.88% 276,817
  1. Stock Market
  2. Stocks
  3. NAVANAPHAR Stock